Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR pooled screen and QuantSeq 3' mRNA sequencing to identify microRNAs (miRNAs) important for Breast Cancer 3D growth [RNA-seq]

ABSTRACT: Breast cancer (BC) is a heterogeneous malignancy with distinct molecular subtypes and clinical characteristics. Tumor-initiating cells (TICs) constitute a small subset of cancer cells responsible for tumor initiation and progression. MicroRNAs (miRNAs), small non-coding RNA molecules, play a pivotal role in regulating gene expression and have been implicated in cancer development and progression. In this study, we conducted genome-wide CRISPR-Cas9 screens within 3D tumorspheres of two BC cell lines, MCF7 (ER+) and HCC1395 (TNBC). Our objective was to identify miRNAs that govern TIC viability, employing CRISPR/Cas9 pooled screens that targeted a total of 19,052 genes and 1,864 miRNAs. By suppressing relevant miRNAs following QuantSeq 3' mRNA sequencing we identify the genes regulated by those miRNAs

ORGANISM(S): Homo sapiens

PROVIDER: GSE243883 | GEO | 2024/03/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CRISPR pooled screen and QuantSeq 3' mRNA sequencing to identify microRNAs (miRNAs) important for Breast Cancer 3D growth [CRISPR screen]

Project description:Breast cancer (BC) is a heterogeneous malignancy with distinct molecular subtypes and clinical characteristics. Tumor-initiating cells (TICs) constitute a small subset of cancer cells responsible for tumor initiation and progression. MicroRNAs (miRNAs), small non-coding RNA molecules, play a pivotal role in regulating gene expression and have been implicated in cancer development and progression. In this study, we conducted genome-wide CRISPR-Cas9 screens within 3D tumorspheres of two BC cell lines, MCF7 (ER+) and HCC1395 (TNBC). Our objective was to identify miRNAs that govern TIC viability, employing CRISPR/Cas9 pooled screens that targeted a total of 19,052 genes and 1,864 miRNAs. By suppressing relevant miRNAs following QuantSeq 3' mRNA sequencing we identify the genes regulated by those miRNAs

2024-03-31 | GSE243882 | GEO

The identification of genetic vulnerabilities in head and neck cancers for the development of novel therapies

Project description:CRISPR/Cas9 lethality screens in a set of Asian head and neck cancer cell lines to identify novel targets.

| EGAS00001002204 | EGA

Genomics of Pediatric Renal Medullary Carcinomas

Project description:<p>We derived faithful cancer cell lines from patients with a diagnosis of renal medullary carcinomas (RMC). These models have been sequenced with whole genome, exome and transcriptome technologies along with the patient's primary germline and tumor samples. We took these faithful models and performed loss-of-function genetic perturbation screens (e.g. RNAi and CRISPR-Cas9) along with an orthogonal small molecule screen. We identified the ubiquitin-proteasome system as an important target in RMC as well as other SMARCB1 deficient cancers.</p>

| phs001800 | dbGaP

miRNA expression profiles of HeLa-Cas9 and NCI-N87 cells

Project description:MicroRNAs (miRNAs) play an important role in the regulation of gene expression and are often dysregulated in disease. The recent development of the CRISPR-Cas9 gene-editing system, composed of the Cas9 nuclease in complex with a single guide RNA (sgRNA), allows researchers to direct DNA cleavage at a predetermined site and to conduct genome-scale knockout screens. To determine the functional role of miRNAs in cancer, we designed and constructed a library of 7,382 sgRNAs to target 85% of the 1,881 annotated human miRNA stem-loops. We then examined the role of miRNAs in HeLa cell fitness by monitoring the change in frequency of each sgRNA over time. We identified 44 pro-proliferative miRNAs from two replicate experiments, including miR-31, a known cervical cancer overexpressing miRNA that enhances HeLa cell proliferation. We also examined the role of miRNAs in NCI-N87 gastric cancer cells and identified 10 pro-fitness and 10 anti-fitness miRNAs. In both screens, many of the pro-fitness miRNAs identified are overexpressed in tumors cervical tumors for HeLa or gastric tumors for NCI-N87. In summary, we present a CRISPR miRNA-targeted screen which was able to identify both known and novel fitness-associated miRNAs in the HeLa and NCI-N87 cell lines.

2018-06-21 | GSE110784 | GEO

Effects of mir-483 and mir-663a knockout in human cancer cell lines

Project description:CRISPR/Cas9 knockout screens were performed to identify core fitness miRNA gene in human cancer cell lines.

2024-04-25 | GSE242259 | GEO

Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer

Project description:Purpose: Resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) is a clinical challenge in estrogen receptor (ER) positive (ER+) breast cancer (BC). Cyclin-dependent kinase 7 (CDK7) is a candidate target in endocrine resistant ER+ BC models and selective CDK7 inhibitors (CDK7i) are in clinical development for the treatment of ER+ BC. Nonetheless, the precise mechanisms responsible for the activity of CDK7i in ER+ BC remain elusive. Herein, we sought to unravel these mechanisms. Experimental Design: We conducted multi-omic analyses in ER+ BC models in vitro and in vivo including models with different genetic backgrounds. We also performed genome wide CRISPR knock-out library screens to identify potential therapeutic vulnerabilities in CDK4/6i resistance models. Results: We found that the on-target anti-tumor effects of CDK7 inhibition in ER+ BC are in part p53 dependent, involve cell-cycle inhibition and suppression of c-Myc. Moreover, CDK7 inhibition exhibited cytotoxic effects, distinctive from the cytostatic nature of ETs and CDK4/6i. CDK7 inhibition resulted in suppression of ER phosphorylation at S118, however, long-term CDK7 inhibition resulted in increased ER signaling, supporting the combination of ET with a CDK7i. Lastly, genome wide CRISPR/Cas9 screens identified CDK7 and MYC signaling as putative vulnerabilities in CDK4/6i resistance, and CDK7 inhibition effectively inhibited CDK4/6i resistant models. Conclusions: Taken together, these findings support the clinical investigation of selective CDK7 inhibition combined with ET to overcome treatment resistance in ER+ BC. In addition, our study highlights the potential of increased c-Myc activity and intact p53 as predictors for sensitivity to CDK7 inhibitor-based treatments.

2024-02-12 | GSE230362 | GEO

Integrated Genetic and Pharmacologic Interrogation of Rare Cancers

Project description:<p>Due to the paucity of patient derived models in rare cancers, identification of therapeutic targets remains challenging. We developed a patient derived model, CLF-PED-015-T, from a patient with an undifferentiated sarcoma. From this model, we performed pooled RNAi and CRISPR-Cas9 negative selection screens and integrated that with a small molecule screen. Integration of these data identified CDK4 and XPO1 as potential therapeutic targets.</p>

| phs001121 | dbGaP

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities

Project description:The ability to perturb genes in human cells is crucial for elucidating gene function and holds great potential for finding therapeutic targets for diseases such as cancer. To extend the catalog of human core and context- dependent fitness genes, we have developed a high-complexity second-generation genome-scale CRISPR-Cas9 gRNA library and applied it to fitness screens in five human cell lines. Using an improved Bayesian analytical approach, we consistently discover 5-fold more fitness genes than were previously observed. We present a list of 1,580 human core fitness genes and describe their general properties. Moreover, we demonstrate that context-dependent fitness genes accurately recapitulate pathway-specific genetic vulnerabilities induced by known oncogenes and reveal cell-type-specific dependencies for specific receptor tyrosine kinases, even in oncogenic KRAS backgrounds. Thus, rigorous identification of human cell line fitness genes using a high-complexity CRISPR-Cas9 library affords a high-resolution view of the genetic vulnerabilities of a cell. Additional data can be found at tko.ccbr.utoronto.ca RNAseq of five human cell lines with Cas9 knock-ins.

2015-11-25 | E-GEOD-75189 | biostudies-arrayexpress

Project description:CRISPR knockout screens using Cas9 variants

| PRJNA977711 | ENA

Project description:CRISPR Cas9 genetic screens on TMPRSS2

| PRJNA1101180 | ENA